Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

Five Themes For BIO-Europe 2017

From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.

Brexit Business Strategies Research and Development Strategies

Brexit Ambiguity A Top Priority For Bayer's New UK & Ireland CEO

Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.

Brexit Business Strategies Market Access

Latest From Brexit

Political Bargaining Intensifies Before Vote On EMA’s New Home

In the run-up to Monday’s vote on the EMA’s future home, political horse-trading and vote-swapping behind the scenes makes it difficult to predict which EU city will win the prized agency.

Brexit Regulation

Novo Nordisk CSO Thomsen Assesses The Competition In Diabetes

The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.

Business Strategies Commercial

AZ Chief Scientist Wants Britain To Be Like Boston

A UK Government report is spelling out an achievable vision for the country's life sciences sector which will create an internationally competitive eco-system.

Policy & Regulation Financing

Pharma Calls On UK Govt To Fund Centers of Excellence

The Medicines Manufacturing Industry Partnership says £140m invested in four centers would provide high-skilled jobs and make the UK the first place in the world where drugs can be discovered, made and packaged.

Manufacturing Financing

Ipsen Promotes UK Business; Kidney Cancer Drug Gets NICE Nod

Ipsen's VP of commercial operations for the UK and Ireland outlines how the French company will use managed access programs to get drugs reimbursed on the NHS and describes Ipsen's plans for growth and greater investment in the UK, despite Brexit uncertainties.

Business Strategies Brexit

BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors

In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.

Deals Business Strategies
See All